Revolution Medicines will host an investor webcast on December 2, 2024, to discuss updates on its RAS(ON) inhibitor portfolio.
Quiver AI Summary
Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, announced an investor webcast to share clinical updates on its RAS(ON) inhibitor portfolio. The webcast is scheduled for 8:00 a.m. Eastern Time on December 2, 2024, with a replay available for at least 14 days on the company's website. Revolution Medicines is advancing several RAS(ON) inhibitors in clinical development, including RMC-6236, RMC-6291, and RMC-9805, which target various oncogenic variants of RAS proteins. Additionally, the company is exploring further development opportunities with other RAS(ON) mutant-selective inhibitors and RAS companion inhibitors.
Potential Positives
- Announcement of an investor webcast to provide clinical updates demonstrates transparency and engagement with stakeholders.
- The focus on RAS-addicted cancers highlights the company's specialized niche in oncology, potentially increasing investor interest.
- Showcases a robust pipeline of RAS(ON) inhibitors currently in clinical development, indicating ongoing innovation and growth potential.
- Availability of archived replay ensures that interested parties can access information even if they cannot attend the live event, enhancing communication efforts.
Potential Negatives
- Company is still in the clinical stage, indicating that therapies are not yet available to patients, which may raise concerns about the time to market and potential revenue generation.
- Details about the clinical updates are vague, which leaves investors uncertain about the efficacy or progress of the therapies in development.
- Focus on a niche market of RAS-addicted cancers may limit the company's potential customer base compared to broader oncology treatments.
FAQ
When is the Revolution Medicines investor webcast?
The investor webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024.
How can I access the webcast for Revolution Medicines?
You can access the webcast by clicking the link provided in the press release.
Will there be a replay of the Revolution Medicines webcast?
Yes, an archived replay will be available for at least 14 days on the company's “Events & Presentations” page.
What does Revolution Medicines focus on in its research?
Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers.
What are the key products in Revolution Medicines' RAS(ON) inhibitor portfolio?
The key products include RMC-6236, RMC-6291, and RMC-9805, among others.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RVMD Insider Trading Activity
$RVMD insiders have traded $RVMD stock on the open market 50 times in the past 6 months. Of those trades, 0 have been purchases and 50 have been sales.
Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:
- JEFF CISLINI (General Counsel) has traded it 7 times. They made 0 purchases and 7 sales, selling 22,164 shares.
- STEPHEN MICHAEL KELSEY (See Remarks) has traded it 16 times. They made 0 purchases and 16 sales, selling 108,014 shares.
- MARK A GOLDSMITH (See Remarks) has traded it 17 times. They made 0 purchases and 17 sales, selling 186,165 shares.
- SUSHIL PATEL has traded it 2 times. They made 0 purchases and 2 sales, selling 7,155 shares.
- JACK ANDERS (Chief Financial Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 14,137 shares.
- MARGARET A HORN (Chief Operating Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 58,746 shares.
- BARBARA WEBER sold 5,200 shares.
- LIN WEI (Chief Medical Officer) sold 5,589 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RVMD Hedge Fund Activity
We have seen 146 institutional investors add shares of $RVMD stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BVF INC/IL removed 2,502,600 shares (-41.8%) from their portfolio in Q3 2024
- WELLINGTON MANAGEMENT GROUP LLP removed 2,258,802 shares (-16.5%) from their portfolio in Q3 2024
- LORD, ABBETT & CO. LLC added 1,832,021 shares (+inf%) to their portfolio in Q3 2024
- NORGES BANK added 1,566,942 shares (+556.2%) to their portfolio in Q2 2024
- FARALLON CAPITAL MANAGEMENT LLC added 1,560,000 shares (+16.0%) to their portfolio in Q3 2024
- JANUS HENDERSON GROUP PLC added 1,497,026 shares (+32.3%) to their portfolio in Q3 2024
- ALPHABET INC. removed 1,050,900 shares (-19.8%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here . An archived replay will be available on the “Events & Presentations” page of the Revolution Medicines website at https://ir.revmed.com/events-and-presentations for at least 14 days following the live event.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
